Latest News

WASHINGTON, D.C. – Rx Response  elevated its status to Alert and has activated Rx Open in the aftermath of yesterday’s deadly tornado in Moore, Oklahoma. (www.RxResponse.org).  Rx Response and Rx Open are initiatives of America’s bio-pharmaceutical supply system to help ensure the continued flow of medicine to patients in a severe public health emergency.

Washington, DC –– The Partnership for Prescription Assistance (PPA), a nationwide effort sponsored by America’s biopharmaceutical research companies to help patients obtain access to the medicines they need for free or nearly free, is celebrating its eighth anniversary today.  Since its debut in April 2005, PPA has helped nearly 8 million Americans by connecting them to patient assistance programs. 

As more and more patients look to the Internet for the supply of medicines, IFPMA, PhRMA, EFPIA, and JPMA are united in the effort to protect their safety.

New Orleans, LA – Rx Response Director and PhRMA Associate Vice President for IT & Operations Erin Mullen, PhD., RPh, CEM, received the Outstanding Achievement Award for Preparedness at the National Hurricane Conference in New Orleans today.

Mullen was recognized for her work in transforming Rx Response from a concept to a fully operational disaster preparedness and response program that encompasses the entire bio-pharmaceutical supply system, from manufacturers to distributors to dispensers. 

Recipients recognized for outstanding contributions to the fight against Alzheimer’s disease

Washington, D.C. — The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today the recipients of the first annual Research and Hope Awards. This year’s award honors outstanding achievements in academia, the biopharmaceutical research sector, as well as the patient and caregiving communities to help advance medical progress and patient care for Alzheimer’s disease.

News Room

For press inquiries, please contact Kaelan Hollon at khollon@phrma.org.

For quick reference, view our frequently asked questions.